Ambroxol Shows Promise in Treating Neuropsychiatric Symptoms in Parkinson’s Disease-Related Dementia
Since 1979, ambroxol, an active ingredient commonly found in cough medicines in Europe, has been under the spotlight for its potential in treating neuropsychiatric symptoms in Parkinson’s disease-related dementia. While the drug is not approved for use in the US, Canada, or Australia, a recent gold-standard phase 2 clinical trial has shown promising results.
In the study, 22 participants with Parkinson’s dementia who received a high daily dose of ambroxol for a year demonstrated no worsening of key neuropsychiatric symptoms. In contrast, the 25 patients who received a placebo experienced worsening symptoms, as indicated by an established neuropsychiatric score. Those on ambroxol showed stabilization in symptoms like delusions, hallucinations, anxiety, irritability, apathy, and aberrant motor activity.
Although both groups had similar cognitive scores related to memory and language, participants on ambroxol experienced fewer falls. While no significant improvements in cognition were recorded, the study provides a strong foundation for larger trials.
Genetic Factors and GCase Activity
Notably, participants with a high-risk GBA1 gene for Parkinson’s showed improved cognitive performance on ambroxol. The GBA1 gene variants are associated with lower activity of the enzyme Glucocerebrosidase (GCase), which is linked to the formation of protein clumps in the brain, such as Lewy bodies seen in Parkinson’s dementia.
Recent studies have shown that ambroxol can increase GCase activity significantly. In the trial, individuals on ambroxol exhibited 1.5 times the amount of GCase activity compared to the placebo group.
Potential for Neurodegenerative Conditions
Given ambroxol’s ability to cross the blood-brain barrier, researchers speculate that it could be beneficial in managing neurodegenerative conditions like Parkinson’s, ALS, Gaucher disease, neuroinflammation, or spinal cord injury. Further clinical research is needed to explore these possibilities.
The study’s findings suggest that ambroxol may offer a new treatment avenue for managing Parkinson’s dementia, especially in individuals genetically at risk. With no serious adverse effects reported, except for mild gastrointestinal issues, the drug holds promise in improving brain function and potentially enhancing the quality of life for patients.
Published in JAMA Neurology, this study underscores the importance of exploring the therapeutic potential of ambroxol in neurodegenerative disorders. As research progresses, ambroxol could become a beacon of hope for individuals battling Parkinson’s disease and related dementias.
